(0.02%) 5 071.63 points
(-0.11%) 38 461 points
(0.10%) 15 713 points
(-0.62%) $82.84
(-9.27%) $1.644
(-0.56%) $2 328.90
(-0.61%) $27.20
(-1.11%) $912.60
(0.05%) $0.935
(0.74%) $10.98
(-0.05%) $0.803
(-0.97%) $92.28
Live Chart Being Loaded With Signals
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases...
Stats | |
---|---|
Today's Volume | 17 682.00 |
Average Volume | 66 803.00 |
Market Cap | 158.16M |
EPS | €0 ( 2024-03-28 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.240 |
ATR14 | €0.00800 (0.26%) |
Inventiva SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Inventiva SA Financials
Annual | 2023 |
Revenue: | €17.48M |
Gross Profit: | €17.50M (100.13 %) |
EPS: | €-2.43 |
Q4 | 2023 |
Revenue: | €15.58M |
Gross Profit: | €15.60M (100.15 %) |
EPS: | €-1.120 |
Q2 | 2023 |
Revenue: | €1.90M |
Gross Profit: | €1.44M (75.85 %) |
EPS: | €-1.310 |
Q4 | 2022 |
Revenue: | €12.11M |
Gross Profit: | €11.64M (96.09 %) |
EPS: | €-0.590 |
Financial Reports:
No articles found.
Inventiva SA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators